WO2000064884A1 - Piperidyl-imidazole derivatives, their preparations and therapeutic uses - Google Patents

Piperidyl-imidazole derivatives, their preparations and therapeutic uses Download PDF

Info

Publication number
WO2000064884A1
WO2000064884A1 PCT/DK2000/000186 DK0000186W WO0064884A1 WO 2000064884 A1 WO2000064884 A1 WO 2000064884A1 DK 0000186 W DK0000186 W DK 0000186W WO 0064884 A1 WO0064884 A1 WO 0064884A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
compound according
use
preparation
treatment
pharmaceutical composition
Prior art date
Application number
PCT/DK2000/000186
Other languages
French (fr)
Inventor
Florencio Zaragoza DÖRWALD
Knud Erik Andersen
Tine Krogh JØRGENSEN
Birgitte Schjellerup Wulff
Ingrid Pettersson
Original Assignee
Novo Nordisk A/S
Boehringer Ingelheim International, Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Piperidyl-imidazole derivatives pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is beneficial.

Description

PIPERIDYL--IMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THERAPEUTIC USES

FIELD OF THE INVENTION The present invention relates to novel substituted imidazoles, to methods for their preparation, to the use of these compounds as medicaments, to pharmaceutical compositions comprising the compounds, and to a method of treatment employing these compounds and compositions. The present compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic or agonistic activity. As a result, the compounds are useful for the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor.

BACKGROUND OF THE INVENTION The existence of the histamine H3 receptor has been known for several years and the receptor is of current interest for the development of new medicaments (see eg Stark, H.; Schlicker, E.; Schunack, W., Drugs Put 1996, 21, 507-520; Leurs, R.; Timmerman, H.; Vollinga, R. C, Progress in Drug Research 1995, 45, 107-165). Recently, the human histamine H3 receptor has been cloned, cf Lovenberg, T.W. et al, Molecular Pharmacology, June 1999, 55, 1101-1107. The histamine H3 receptor is a presynaptic autoreceptor located both in the central and the peripheral nervous system, the skin and in organs such as the lung, the intestine, probably the spleen and the gastrointestinal tract. The histamine H3 receptor has been demonstrated to regulate the release of histamine and also of other neurotransmitters such as serotonin and acetylcholine. A histamine H3 receptor antagonist would therefore be expected to increase the release of these neurotransmitters in the brain. A histamine H3 receptor agonist, on the contrary, leads to an inhibition of the biosynthesis of histamine and an inhibition of the release of histamine and also of other neurotransmitters such as serotonin and acetylcholine. These findings suggest that histamine H3 receptor ago- nists and antagonists could be important mediators of neuronal activity. Accordingly, the histamine H3 receptor is an important target for new therapeutics. Several publications disclose the preparation and use of histamine H3 agonists and antagonists.

Thus, US patent No. 5,486,526 (corresponding to WO No. 95/11894) (the University of Toledo) discloses piperidyl-imidazole derivatives, which are stated to be potent histamine H3 receptor antagonists. More particularly, piperidyl-imidazole derivatives of the following formula are disclosed:

Figure imgf000004_0001

wherein Ri i.a. represents hydrogen or an in vivo hydrolyzable group; D represents CH2 or CH2CH2; Z represents O or S; x is 0 or 1 ; n is an integer from 0 to 6; and R2 represents a substituted or unsubstituted linear chain or branched chain alkyl group of up to about 20 carbon atoms, a substituted or unsubstituted carbocyclic group of up to about 20 carbon atoms or a substituted or unsubstituted aryl group of up to about 20 carbon atoms.

The compounds according to the invention differ structurally from these known compounds by bearing a tertiary nitrogen atom in the side chain attached to the nitrogen atom of the piperidinyl group. EP No. 0 494 010 (INSERM et al.) discloses piperidine derivatives of the following general formula which are stated to possess histamine H3 receptor antagonistic activity:

Figure imgf000005_0001

wherein R-i i.a. represents a hydrogen atom; and R i.a. represents

i) a group COR3 wherein R3 i.a. represents

a linear chain or branched chain alkyl group of from 1 to 11 carbon atoms,

a group -(CH2)nR wherein n is an integer from 1 to 10 and R4 i.a. represents a non-aromatic carbocyclic ring system, a phenyl group optionally su bstituted or thionyl ,

a group -CH=CHRβ wherein R8 represents a non-aromatic carbocyclic ring system, or

a secondary amine group -NH(CH2)nRg wherein n is an integer from 1 to 5 and Rg represents a non-aromatic carbocyclic ring system or a phenyl group optionally substituted, or

ii) a group -C(=S)NH(CH2)nR9 wherein n is an integer from 1 to 5 and Rg represents a non-aromatic carbocyclic ring system or a phenyl group optionally substituted.

The present compounds differ from these known compounds by bearing a tertiary nitrogen atom in the side chain attached to the nitrogen atom of the piperidinyl group. Furthermore, EP No. 0 197 840 (INSERM et al.) discloses piperidine derivaties of the following general formula which are stated to possess histamine H3 receptor antagonistic activity:

Figure imgf000006_0001

wherein Ri is hydrogen, methyl or ethyl, R i.a. is hydrogen, and R2 i.a. represents a linear chain or branched chain Cι-6-alkyl group, a 3-(1-benzimidazolonyl) propyl group or a group -(CH2)n-X-(phenyl-R3) wherein n is an integer from 0 to 3, X i.a. is -NH-, a bond or -CH=CH- and R3 i.a. represents hydrogen, methyl, halogen or trifluoromethyl.

When R2 represents 3-(1-benzimidazolonyl) propyl a tertiary nitrogen atom is present in the side chain of the piperidinyl group of the known compounds. In this case, however, the tertiary nitrogen atom is forming part of a specific ring system viz. the 1- benzimidazolonyl group, which is not embraced by the present invention. None of the remaining known compounds contains a tertiary nitrogen atom in the side chain attached to the nitrogen atom of the piperidinyl group. Accordingly, the know com- pounds differ from the present compounds.

In view of the art's interest in histamine H3 receptor agonists and antagonists, novel compounds which interact with the histamine H3 receptor would be a highly desirable contribution to the art. The present invention provides such a contribution to the art being based on the finding that a specific class of substituted imidazole compounds has a high and specific affinity to the histamine H3 receptor. Some of these substituted imidazole derivatives are novel per se thereby constituting a further aspect of the invention. Due to their interaction with the histamine H3 receptor, the present compounds are useful in the treatment and/or prevention of a wide range of conditions and disorders in which an interaction with the histamine H3 receptor is beneficial. Thus, the com- pounds may find use eg in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system.

DEFINITIONS In the structural formulas given herein and throughout the present specification, the following terms have the indicated meaning:

The term "Cι-6-alkyl" as used herein represents a branched or straight hydrocarbon group having from 1 to 6 carbon atoms. Typical Cι-6-alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, ferf-butyl, pen- tyl, isopentyl, hexyl, isohexyl and the like.

The term "Cι-6-alkoxy" as used herein, alone or in combination, refers to the radical -O-C-ι-6-alkyl where Cι-6-alkyl is as defined above. Representative examples are methoxy, ethoxy, n-propoxy, isopropoxy, butoxy, sec-butoxy, fetf-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy and the like.

The term "C3-8-cycloalkyl" as used herein represents a carbocyclic group having from 3 to 8 carbon atoms. Representative examples are cyclopropyl, cyclobutyl, cyclopen- tyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like.

The term "aryl" as used herein is intended to include carbocyclic aromatic ring systems such as phenyl, naphthyl (1-naphthyl or 2-naphthyl), anthracenyl (1-anthracenyl, 2- anthracenyl, 3-anthracenyl), phenanthrenyl, fluorenyl, indenyl and the like. Aryl is also intended to include the partially hydrogenated derivatives of the carbocyclic systems enumerated above. Non-limiting examples of such partially hydrogenated derivatives are 1-(1 ,2,3,4-tetrahydronaphthyl) and 2-(1 ,2,3,4-tetrahydronaphthyl). The term "heteroaryl" as used herein is intended to include heterocyclic aromatic ring systems containing one or more heteroatoms selected from nitrogen, oxygen and sulfur such as furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl, isothiazolyl, triazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, thiadiazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, quinazolinyl, quinolizinyl, quinolinyl, isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl and the like. Heteroaryl is also intended to include the partially or fully hydrogenated derivatives of the heterocyclic systems enumerated above. Non-limiting examples of such partially or fully hydrogenated derivatives are pyrrolinyl, pyrazolinyl, indolinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepinyl, diazepinyl, morpholinyl, thiomorpholinyl, oxazolidinyl, oxazolinyl, oxazepinyl, aziridinyl and tetrahydofuranyl.

The term "halogen" means fluorine, chlorine, bromine or iodine.

As used herein, the phrase "mono-, bi- or polycyclic ring system" is intended to include all the carbocyclic and heterocyclic ring systems that R3 and R4 according to their definitions are able to form with the linker group and the nitrogen atom to which they are attached. Non-limiting examples of such ring systems are systems containing one to five cycles, eg two to four cycles such as 5,11-dihydro-5H-dibenz- [b,e][\ ,4]oxazepin-5-yl, 5,11-dihydro-5H-dibenz[ι ,e][1 ,4]thiazepin-5-yl, 10,11-dihydro- 5H-dibenzo[i->,/]azepin-5-yl, phenothiazin-10-yl, phenoxazin-10-yl and 9H- tribenzo[/3,d,/]azepin-9-yl which may optionally be substituted, eg with halogen or C-i- 6-alkoxy.

Certain of the above defined terms may occur more than once in the structural formulas, and upon such occurrence each term shall be defined independently of the other.

The term "optionally substituted" as used herein means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent the substituents may be the same or different.

As used herein, the phrase "a functional group which can be converted to hydrogen in vivo" is intended to include any group which upon administering the present compounds to the subjects in need thereof can be converted to hydrogen eg enzymati- cally or by the acidic environment in the stomach. Non-limiting examples of such groups are acyl, carbamoyl, monoalkylated carbamoyl, dialkylated carbamoyl, alkoxycarbonyl, alkoxyalkyl groups and the like such as Cι-6-alkanoyl, aroyl, Cι-6-alkylcarbamoyl, di-Ci-6-alkylcarbamoyl, Cι-6-alkoxycarbonyl and C-i-6-alkoxy-Ci-6-alkyl.

As used herein, the phrase "diseases and disorders related to the histamine H3 receptor" is intended to include any disease or disorder in which an effect, either an- tagonistic or agonistic, on the histamine H3 receptor is beneficial.

DESCRIPTION OF THE INVENTION

The present invention relates to novel substituted imidazoles of the general formula

Figure imgf000009_0001

wherein

R1 is hydrogen or a functional group, which can be converted to hydrogen in vivo;

R2 is hydrogen, cyano, halogen or Cι-6-alkyl; wherein d-6-alkyl is optionally substituted with cyano, halogen, amino, ni- tro, trifluoromethyl or Cι-6-alkoxy;

X is -C(=O)-, -C(=S)- or -CH2-;

n is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10; and

R3 and R4 independently are

C3-8-cycloalkyl optionally substituted with halogen, C-ι-6-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl;

aryl optionally substituted with halogen, Cι-6-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl;

heteroaryl optionally substituted with halogen, C-i-β-alkoxy, C-ι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl; or

C-i-6-alkyl optionally substituted with halogen, C-ι-6-alkoxy, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl; wherein C3-8-cycloalkyl, aryl and heteroaryl optionally are substituted with halogen, C-i-β-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino or cyano;

which groups R3 and R4 optionally may be connected by one or more bridging linkers to form, together with the nitrogen atom to which they are attached, a mono-, bi- or polycyclic ring system;

as well as any optical or geometric isomer or tautomeric form thereof including mix- tures of these or a pharmaceutically acceptable salt thereof. In a preferred embodiment R3 and R4 may optionally be connected by one or more bridging linkers independently selected from a bond, C-ι_4-alkylene, C2-4-alkenylene, -(CH2)o-4-O-(CH2)o-4-, -(CH2)U-4-S-(CH2)o-4-, phenylene and biphenylene to form, together with the nitrogen atom to which they are attached, a mono-, bi- or polycyclic ring system.

In a preferred embodiment of the invention R1 and R2 are both hydrogen.

In another preferred embodiment of the invention X is -C(=O)- or -CH2-.

In still another preferred embodiment of the invention n is 1 to 5, preferably 2, 3 or 4.

In yet another preferred embodiment of the invention R3 and R4 are both aryl, preferably phenyl optionally substituted as defined above for formula I.

Preferably, the phenyl groups are unsubstituted.

When the phenyl groups are substituted the substituents are preferably selected from halogen, C-ι-6-alkoxy such as methoxy or ethoxy, Cι_6-alkyl such as methyl, ethyl, n- propyl, i-propyl, i-butyl or fe/ -butyl, trifluoromethyl, nitro, amino and cyano.

In a further preferred embodiment of the invention R3 and R4 are connected via one or more bridging linkers selected from a bond, Cι_ -alkylene such as ethylene or pro- pylene, C2--.-alkenylene such as ethenylene or propenylene, -(CH2)o-4-O-(CH2)o-4- such as -O- or oxy-C-ι.4-alkylene such as oxymethylene, oxyethylene or oxypropyl- ene,

-(CH2)o-4-S-(CH2)o-4- such as -S- or thio-C-ι_4-alkylene such as thiomethylene, thio- ethylene or thiopropylene, phenylene and biphenylene to form, together with the nitrogen atom to which they are attached, a mono-, bi- or polycyclic ring system such as a mono-, bi-, tri- or tetracyclic system.

Preferably, R3 and R4 are connected via one linker. Preferably, the linker is selected from C- -alkylene such as ethylene or propylene, -S-, phenylene such as 1 ,2-phenylene and oxy-C-ι-4-alkylene such as oxyethylene or oxypropylene. Preferred among these is Cι- -alkylene such as ethylene or propylene, especially ethylene.

In still a preferred embodiment of the invention R3 and R4 are both representing phenyl groups which are connected via a Cι-4-alkylene linker, preferably ethylene. The phenyl groups may optionally be substituted as defined above for formula I but preferably they are unsubstituted.

When they are substituted the substituents are preferably selected from halogen, C 1-6-alkoxy such as methoxy or ethoxy, C-ι-6-alkyl such as methyl, ethyl, n-propyl, i- propyl, i-butyl or fert-butyl, trifluoromethyl, nitro, amino and cyano.

Specific examples of the above-preferred embodiments of the present invention are the following compounds:

3-(10,11 -Dihydro-5H-dibenzo[j ,fjazepin-5-yl)-1 -(4-(1 H-imidazol-4-yl)piperidin-1 - yl)propan-1-one;

5-(3-(4-(1H-lmidazol-4-yl)piperidin-1-yl)propyl)-10,11-dihydro-5H-dibenzo[b,/]azepine;

4-(10,11-Dihydro-5H-dibenzo[b,f)azepin-5-yl)-1-(4-(1b/-imidazol-4-yl)piperidin-1- yl)butan-1-one;

4-Diphenylamino-1 -(4-(1 H-imidazol-4-yl)piperidin-1 -yl)butan-1 -one;

5-(4-(4-(1H-lmidazol-4-yl)piperidin-1-yl)butyl)-10,11-dihydro-5H-dibenzo[j ,/]azepine;

1 -(4-(1 H-lmidazol-4-yl)piperidin-1 -yl)-4-(phenothiazin-10-yl)butan-1 -one; 4-(2-Bromo-10,11-dihydro-5H-dibenzo[i , ]azepin-5-yl-1-(4-(1H-imidazol-4-yl)piperi- din-1-yl)butan-1-one;

4-(9H-Tribenzo[6,of, ]azepin-9-yl)-1 -(4-(1 H-imidazol-4-yl)piperidin-1 -yl)butan-1 -one; and

4-(5,11-Dihydro-5H-dibenzo[/-»,e][1 ,4]oxazepin-5-yl)-1-(4-(1H-imidazol-4-yl)piperidin- 1-yl)butan-1-one.

The compounds of the present invention may have one or more asymmetric centres and it is intended that any optical isomers, as separated, pure or partially purified optical isomers or racemic mixtures thereof are included within the scope of the invention.

Furthermore, when a double bond or a fully or partially saturated ring system is pre- sent in the molecule geometric isomers may be formed. It is intended that any geometric isomers, as separated, pure or partially purified geometric isomers or mixtures thereof are included within the scope of the invention. Likewise, molecules having a bond with restricted rotation may form geometric isomers. These are also intended to be included within the scope of the present invention.

Furthermore, the compounds of the present invention may exist in different tautomeric forms and it is intended that any tautomeric forms, which the compounds are able to form, are included within the scope of the present invention.

The present invention also encompasses pharmaceutically acceptable salts of the present compounds. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.

Also intended as pharmaceutically acceptable acid addition salts are the hydrates, which the present compounds are able to form.

The acid addition salts may be obtained as the direct products of compound synthe- sis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.

The compounds of the present invention may form solvates with standard low mo- lecular weight solvents using methods known to the skilled artisan. Such solvates are also contemplated as being within the scope of the present invention.

The invention also encompasses prodrugs of the present compounds, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances. In general, such prodrugs will be functional derivatives of the compounds, which are readily convertible in vivo into the present compounds. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The invention also encompasses active metabolites of the present compounds. The compounds of the present invention interact with the histamine H3 receptor and may thus be used for the treatment of a wide range of conditions and disorders in which histamine H3 receptor interactions are beneficial.

Accordingly, in another aspect the present invention relates to a compound of the general formula I as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof for use as a medicament.

The invention also relates to pharmaceutical compositions comprising, as an active ingredient, at least one compound of the formula I as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers or diluents.

Furthermore, the invention relates to the use of a compound of the general formula I as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment and/or prevention of disorders or diseases related to the histamine H3 receptor.

In still another aspect, the invention relates to a method for the treatment and/or prevention of disorders or diseases related to the histamine H3 receptor the method comprising administering to a subject in need thereof an effective amount of a compound of the formula I as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.

More particularly, the present compounds may possess histamine H3 receptor antagonistic activity and would accordingly be useful in the treatment of a wide range of conditions and disorders in which a histamine H3 receptor blockade is beneficial. In a preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the reduction of weight.

In a preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of overweight or obesity.

In another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the suppression of appetite or satiety induction.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the prevention and/or treatment of disorders and diseases related to overweight or obesity such as atheroscle- rosis, hypertension, IGT (impaired glucose tolerance), diabetes, especially Type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), dyslipidaemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers.

In yet a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the prevention and/or treatment of eating disorders such as bulimia and binge eating.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of IGT.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or preven- tion of Type 2 diabetes. In another preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to Type 2 diabetes.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.

The compounds of the present invention may also be used for the treatment of airway disorders such as asthma, as anti-diarrhoeals and for the modulation of gastric acid secretion.

Furthermore, the compounds of the present invention may be used for the treatment of diseases associated with the regulation of sleep and wakefulness and for the treatment of narcolepsy and attention deficit disorders.

Moreover, the compounds of the invention may be used as stimulants or as sedatives.

The present compounds may also be used for the treatment of conditions associated with epilepsy. Additionally, the present compounds may be used for the treatment of motion sickness and vertigo. Furthermore, they may be useful as regulators of hypo- thalamo-hypophyseal secretion, antidepressants, modulators of cerebral circulation, and in the treatment of irritable bowel syndrome.

Further, the compounds of the present invention may be used for the treatment of dementia and Alzheimer's disease.

The present novel compounds may also interact with the vanilloid receptors, the serotonin receptors, and the adrenergic receptors and may be useful for the treatment of diseases associated with these receptors. Hence, the compounds of the present invention may be vanilloid receptor agonists, and thus be useful for the treatment of obesity by enhancement of the metabolic rate and energy expenditure. Further, by virtue of their interaction with the vanilloid receptor the compounds of the present invention may be useful for the treatment of pain or neurogenic inflammation or in- flammatory painful conditions.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the vanilloid receptor such as for the treat- ment and/or prevention of pain, neurogenic inflammation or obesity.

Furthermore, the present compounds may interact with the 5-HT3 receptor (sero- tonin-3-receptor) and may accordingly be useful as antiemetics, in particular the chemotherapy-induced emesis. Further potential applications of 5-HT3 antagonists include treatment of central nervous system disorders such as anxiety, schizophrenia, drug abuse and withdrawal symptoms, and pathological and age-associated amnesia.

In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the serotonin-3 receptor (5-HT3) such as for the treatment of emesis.

Furthermore, the present compounds may interact with the adrenergic alpha-2 recep- tor and thus be useful for the treatment of hypertension and of conditions associated with overexpression or hypersensitization of the adrenergic alpha-2 receptor, especially obesity, withdrawal symptoms to an adrenergic alpha-2 agonist, neurological disorders (especially orthostatic hypotension), multiple system atrophy, diabetes mel- litus, benign prostatic hyperplasia or drug induced sensitization of the adrenergic al- pha-2 receptor. Moreover, the compounds of the present invention, by virtue of their interaction with the alpha-2 receptor, may be useful as sedatives and hypnotics (sleep inducing agents) or as stimulants. In a further preferred embodiment of the invention the present compounds are used for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the alpha-2 adrenergic receptor such as for use as a sleep inducing agent.

The present compounds may be administered in combination with one or more further pharmacologically active substances eg selected from antiobesity agents, antidiabet- ics, antihypertensive agents, agents for the treatment and/or prevention of complica- tions resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.

Thus, in a further aspect of the invention the present compounds may be administered in combination with one or more antiobesity agents or appetite regulating agents.

Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte- stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed serotonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR (peroxisome proliferator- activated receptor) modulators, RXR (retinoid X receptor) modulators or TR β ago- nists.

In one embodiment of the invention the antiobesity agent is leptin. In another embodiment the antiobesity agent is dexamphetamine or amphetamine.

In another embodiment the antiobesity agent is fenfluramine or dexfenfluramine.

In still another embodiment the antiobesity agent is sibutramine.

In a further embodiment the antiobesity agent is orlistat.

In another embodiment the antiobesity agent is mazindol or phentermine.

Suitable antidiabetics comprise insulin, GLP-1 (glucagon like peptide-1 ) derivatives such as those disclosed in WO 98/08871 to Novo Nordisk A/S, which is incorporated herein by reference as well as orally active hypoglycaemic agents.

The orally active hypoglycaemic agents preferably comprise sulphonylureas, bigua- nides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon antagonists such as those disclosed in WO 99/01423 to Novo Nordisk A/S and Agouron Pharmaceuticals, Inc., GLP-1 agonists, potassium channel openers such as those disclosed in WO 97/26265 and WO 99/03861 to Novo Nordisk A/S which are incorporated herein by reference, insulin sensitizers, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimulation of glu- coneogenesis and/or glycogenolysis, glucose uptake modulators, compounds modifying the lipid metabolism such as antihyperiipidemic agents and antilipidemic agents, compounds lowering food intake, PPAR and RXR agonists and agents acting on the ATP-dependent potassium channel of the β-cells.

In one embodiment of the invention the present compounds are administered in combination with insulin.

In a further embodiment the present compounds are administered in combination with a sulphonylurea eg tolbutamide, glibenclamide, glipizide or glicazide. In another embodiment the present compounds are administered in combination with a biguanide eg metformin.

In yet another embodiment the present compounds are administered in combination with a meglitinide eg repaglinide.

In still another embodiment the present compounds are administered in combination with a thiazolidinedione eg troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 to Dr. Reddy's Research Foundation.

Furthermore, the present compounds may be administered in combination with the insulin sensitizers disclosed in WO 99/19313 to Dr. Reddy's Research Foundation.

In a further embodiment the present compounds are administered in combination with an α-glucosidase inhibitor eg miglitol or acarbose.

In another embodiment the present compounds are administered in combination with an agent acting on the ATP-dependent potassium channel of the β-cells eg tolbu- tamide, glibenclamide, glipizide, glicazide or repaglinide.

Furthermore, the present compounds may be administered in combination with nateglinide.

In still another embodiment the present compounds are administered in combination with an antihyperiipidemic agent or antilipidemic agent eg cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyrox- ine.

In a further embodiment the present compounds are administered in combination with more than one of the above-mentioned compounds eg in combination with a sulphonylurea and metformin, a sulphonylurea and acarbose, repaglinide and met- formin, insulin and a sulphonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.

Furthermore, the present compounds may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (an- giotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosi- nopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α- blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gen- naro, Ed., Mack Publishing Co., Easton, PA, 1995.

It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.

PHARMACEUTICAL COMPOSITIONS The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those dis- closed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and paren- teral (including subcutaneous, intramuscular, intrathecal, intravenous and intrader- mal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.

Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well-known in the art.

Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.

Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.

Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day adminis- tered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.

The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain of from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.

For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.

The compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. One example is an acid addition salt of a compound having the utility of a free base. When a compound according to the invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of the compound according to the invention with a chemical equivalent of a pharmaceutically acceptable acid, for example, inorganic and organic acids. Representative examples are mentioned above. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion.

For parenteral administration, solutions of the present compounds in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitable buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water. Similarly, the carrier or diluent may include any sustained release material known in the art such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds according to the invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. These formulations may be in the form of powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion.

If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet, which may be prepared by conventional tabletting techniques, may contain:

Core: Active compound (as free compound or salt thereof) 5.0 mg

Lactosum Ph. Eur. 67.8 mg

Cellulose, microcryst. (Avicel) 31.4 mg

Amberlite 1.0 mg

Magnesii stearas Ph. Eur. 0.25 mg Coating:

HPMC approx. 9 mg

Mywacett 9-40 T* approx. 0.9 mg

*Acylated monoglyceride used as plasticizer for film coating.

If desired, the pharmaceutical composition of the invention may comprise the compound of the formula I in combination with one or more other pharmacologically ac- tive substances.

The preparation of the compounds according to the invention can be realized in many ways.

The compounds of formula I wherein X is -C(=O)- and n, R1, R2, R3 and R4 are as defined for formula I may be prepared by the following method A:

Figure imgf000026_0001

(II) (III)

A compound of formula II wherein R1 and R2 are as defined for formula I may be reacted with a compound of formula III wherein R3, R4 and n are as defined for formula I and P is a suitable group providing an activated carboxylic acid derivative such as an acid chloride, an acid fluoride, an acid imidazolide, a N- hydroxybenzotriazolyl ester, an optionally substituted phenyl ester or it may be a symmetric anhydride, to give a compound of formula I wherein X is -C(=O)-. This acylation reaction may be carried out in a solvent such as dichloromethane, Λ/,/V-dimethylformamide, acetonitrile or Λ/-methyl-2-pyrrolidone at a temperature up to reflux temperature for the solvent used for eg 1 - 200 h. The reaction may be carried out in the presence of a base.

Compounds of formulas II and III are either commercially available or may readily be prepared by methods familiar to those skilled in the art.

Alternatively, the compounds of formula I wherein X is CH2 and n, R1, R2, R3 and R4 are as defined for formula I may be prepared by the following method B:

Figure imgf000027_0001

A compound of formula II wherein R1 and R2 are as defined for formula I may be reacted with a compound of formula IV wherein R3, R4 and n are as defined for formula I and W is a suitable leaving group such as halogen, p-toluenesulfonate or mesylate to give a compound of formula I. This alkylation reaction may be carried out in a solvent such as acetonitrile, acetone, Λ/,Λ/-dimethyiformamide, dibutyl ether, 2-butanone, ethyl acetate, tetrahydrofuran or toluene in the presence of a base eg potassium carbonate, sodium hydride and a catalyst, eg an alkali metal iodide at a temperature up to reflux temperature for the solvent used for eg 1 - 200 h.

Compounds of formulas II and IV are either commercially available or may readily be prepared by methods familiar to those skilled in the art. EXAMPLES

In the examples the following terms are intended to have the following, general meanings:

DMSO: dimethylsulfoxide THF: tetrahydrofuran m.p.: melting point

NMR spectra were recorded on Bruker 300 MHz and 400 MHz instruments. HPLC-MS was performed on a Perkin Elmer instrument (API 100), and HPLC-systems from

Merck-Hitachi (Hibar™ RT 250-4, Lichrosorb™ RP 18, 5.0 μm, 4.0 x 250 mm, gradient elution, 20 % to 80 % acetonitrile in water within 30 min, 1.0 ml/min, detection at 254 nm) and Waters (Symmetry™, C-ι8, 3.5 μm, 3.0 x 150 mm, gradient elution, 5 % to 90 % acetonitrile in water within 15 min, 1.0 ml/min, detection at 214 nm) were used.

EXAMPLE 1

3-(10, 11 -Dihydro-5H-dibenzo[b ,/]azepin-5-yl)-1 -(4-(1 H-imidazol-4-yl)piperidin-1 yl)propan-1-one

Figure imgf000028_0001

Following method A 10,11-dihydro-5/-/-dibenzo[b,/]azepine (50.0 g, 0.3 mol) was dissolved in Λ/,/V-dimethylformamide (700 ml). Under a nitrogen atmosphere, sodium hydride (12.3 g, 0.31 mol, 60 % dispersion in oil) was added in portions and the resulting mixture was stirred at 50 °C for 2 h. 3-Bromopropionic acid ethyl ester (65 ml, 0.51 mol) was added over 1.5 h and the mixture was stirred for 15 minutes before an additional amount of 3-bromopropionic acid ethyl ester (33 ml, 0.26 mol) was added over 15 minutes. The reaction mixture was heated at reflux temperature overnight. After cooling, the mixture was evaporated in vacuo, and the residue was suspended in dichloromethane (150 ml). The solid was filtered off and the filtrate was evaporated in vacuo. The residue was purified in portions by column chromatography on silica gel using dichloromethane as eluent, affording 5.1 g (7 %) of 3-(10,11-dihydro-5H- dibenzo[ιb,/]azepin-5-yl)propionic acid ethyl ester as an oil.

TLC: Rf = 0.54 (SiO2: dichloromethane).

The above ester (1.01 g, 3.42 mmol) was dissolved in ethanol (25 ml) and sodium hydroxide (0.71 g, 18 mmol) dissolved in water (5 ml) was added. The mixture was stirred at room temperature for 2 h. The mixture was acidified to pH ~3 using 1 M hydrochloric acid, and extracted with dichloromethane (2 x 35 ml). The organic extracts were dried (MgSO ) and evaporated in vacuo to give 3-(10,11-dihydro-5H- dibenzo[j ,/]azepin-5-yl)propionic acid in quantitative yield.

4-(4-Piperidyl)imidazole dihydrochloride (0.49 g, 2.2 mmol) was dissolved in metha- nol (5 ml) and sodium methoxide in methanol (0.8 ml, 30 %) was added. The mixture was stirred under nitrogen at room temperature for 1.5 h. At the same time, carbonyl diimidazol (0.33 g, 2.1 mmol) was dissolved in dichloromethane (4 ml), the above carboxylic acid (0.55 g, 2.1 mmol) was dissolved in dichloromethane (4 ml) and added, and the resulting mixture was stirred under nitrogen at room temperature for 1.5 h. The methanol solution was evaporated in vacuo and stripped with dichloromethane and the activated carboxylic acid mixture was added to the residue. The re- action mixture was stirred overnight at room temperature. Water (10 ml) and dichloromethane (50 ml) were added and the phases were separated. The dichloromethane phase was dried (MgS0 ) and evaporated in vacuo. The residue was purified by column chromatography on silica gel (120 ml) using a mixture of methanol and ethyl acetate (1 :5) as eluent to give 0.41 g (50 %) of the title compound as an amorphous product.

TLC: Rf = 0.28 (SiO2: methanol/ethyl actetate = 1 :5). Calculated for C25H28N4O, H2O:

C, 71.75 %; H, 7.22 %; N, 13.38 %; Found:

C, 71.49 %; H, 7.13 %; N, 13.59 %.

EXAMPLE 2

5-(3-(4-(1H-lmidazol-4-yl)piperidin-1-yl)propyl)-10,11-dihydro-5H-dibenzo[i-),/]azepine

Figure imgf000030_0001

Following method B 4-(4-piperidyl)imidazole dihydrochloride (0.25 g, 1.1 mmol), 5-(3- chloropropyl)-10,11-dihydro-5H-dibenzo[f),/]azepine (0.3 g, 1.1 mmol), potassium carbonate (0.46 g, 3.3 mmol) and potassium iodide (0.37 g, 2.2 mmol) were mixed in acetonitrile (10 ml) and the mixture was heated at reflux temperature for 20 h. After cooling, the mixture was filtered and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel (125 ml) using a mixture of ethyl acetate and methanol (4:1 ) as eluent, affording 0.13 g (31 %) of the title compound.

TLC: Rf = 0.15 (SiO2: ethyl acetate/methanol = 4:1 ).

Calculated for C25H3oN4, 1.25 H2O, 0.2 C4H8O2: C, 72.64 %; H, 8.06 %; N, 13.13 %; Found: C, 72.68 %; H, 7.93 %; N, 12.81 %. EXAMPLE 3

4-(10, 11 -Dihydro-5H-dibenzo[j ,f]azepin-5-yl)-1 -(4-(1 H-imidazol-4-yl)piperidin-1 - yl)butan-1-one

Figure imgf000031_0001

Following method A 5-(3-chloropropyl)-10,11-dihydro-5H-dibenzo[b,/]azepine (2.5 g, 9.2 mmol) was dissolved in Λ/,Λ/-dimethylformamide (50 ml) and cooled on an ice- bath. Potassium cyanide (1.2 g, 18.4 mmol) was added in portions over 15 minutes and the reaction mixture was stirred on an icebath for 1 h and subsequently at room temperature for 6 days. Water was added (70 ml) and the mixture was extracted with toluene (100 ml). The toluene extract was dried (MgSO ), evaporated in vacuo and stripped with dichloromethane. The residue was purified by column chromatography on silica gel (150 ml) using a mixture of dichloromethane and heptane (4:1 ) as eluent to give 1.81 g (75 %) of 4-(10,11-dihydro-5H-dibenzo[b,/]azepin-5-yl)butyronitriie as an oil.

TLC: Rf = 0.53 (SiO2: dichloromethane).

The above nitrile (0.6 g, 2.3 mmol) was suspended in ethanol (6 ml). Potassium hydroxide (0.75 g, 13.4 mmol) was dissolved in water (2.5 ml) and added. The mixture was heated at reflux temperature overnight. After cooling, water (10 ml) was added and the solution was washed with toluene (15 ml). The aqueous solution was acidified with ~ 15 % hydrochloric acid (3 ml) and extracted with dichloromethane. The organic phase was evaporated in vacuo to give 0.63 g (97 %) of 4-(10,11-dihydro-5H- dibenzo[f ,/]azepin-5-yl)butyric acid as an oil, which solidified on standing. 4-(4-Piperidyl)imidazole dihydrochloride (0.25 g, 1.1 mmol) was dissolved in methanol (4 ml) and 30 % sodium methoxide in methanol (0.42 ml, 2.3 mmol) was added. The mixture was stirred under nitrogen at room temperature for 1.5 h. At the same time, carbonyl diimidazol (0.17 g, 1.1 mmol) was dissolved in dichloromethane (5 ml), the above carboxylic acid (0.30 g, 1.11 mmol) was added and the resulting mixture was stirred under nitrogen at room temperature for 1.5 h. The methanol solution was evaporated in vacuo and stripped with dichloromethane (8 ml) and the activated carboxylic acid mixture was added to the residue. The reaction mixture was stirred over- night at room temperature. Water (10 ml) was added and the mixture was extracted with dichloromethane. The dichloromethane extracts were dried (MgSO ) and evaporated in vacuo. The residue was purified by column chromatography on silica gel (50 ml) using a mixture of methanol and ethyl acetate (1 :4) as eluent to give 0.28 g (60 %) of the title compound as an amorphous product.

TLC: Rf = 0.35 (SiO2: methanol/ethyl acetate = 1 :4).

Calculated for C26H3oN4O, 0.75 H2O: C, 72.95 %; H, 7.42 %; N, 13.09 %; Found: C, 72.68 %; H, 7.46 %; N, 12.85 %.

EXAMPLE 4

4-Diphenylamino-1 -(4-(1 H-imidazol-4-yl)piperidin-1 -yl)butan-1 -one

Figure imgf000033_0001

Following method A diphenylamine (7.6 g, 45 mmol) was dissolved in dry diglyme (30 ml). Under a nitrogen atmosphere, sodium hydride (2.0 g, 50 mmol, 60 % dispersion in oil) was added in portions and the resulting mixture was stirred at 120 °C for 1 h. The mixture was cooled to 40 °C and 3-bromo-1 -propyl tetrahydro-2-pyranyl ether (11.2 g, 50 mmol) was added and the reaction was heated to 130 °C over 30 minutes and then stirred at this temperature for 2 h. The reaction mixture was cooled to room temperature, poured into water (300 ml) and extracted with ethyl acetate (2 x 200 ml). The combined organic extracts were dried (Na2SO4) and the solvent was evaporated in vacuo. The residue was dissolved in 2-propanol (150 ml) and 4 N sulfuric acid (25 ml) was added. The mixture was stirred at 60 °C for 30 minutes, half of the solvent was evaporated in vacuo and the mixture was diluted with water (300 ml) and neutralised with 4 N sodium hydroxide. The mixture was extracted with ethyl acetate (2 x 200 ml), the combined organic extracts were dried (Na2SO4) and the solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel (150 g) using a mixture of heptane and tetrahydrofuran (8:2) to give 4.7 g (46 %) of 3- diphenylamino-1-propanol as an oil.

The above alcohol (3.8 g, 16.7 mmol) was dissolved in dry tetrahydrofuran (50 ml), triethylamine (2.5 ml, 18.4 mmol) was added and the reaction mixture was stirred at room temperature, while methanesulfonylchloride (1.9 g, 16.7 mmol) was added dropwise. The reaction mixture was stirred for 2 h, the mixture was filtered and the solvent was evaporated in vacuo. The residue was dissolved in dry dimethylsulfoxide (25 ml) and potassium cyanide (2.2 g, 33 mmol) was added. The reaction mixture was heated to 85 °C and an additional amount of dry dimethylsulfoxide (25 ml) was added. Stirring was continued at 85 °C for 3 h. The reaction mixture was cooled and poured into cold water (500 ml) and extracted with ethyl acetate (2 x 200 ml). The combined organic phases were washed with water (100 ml), brine (100 ml) and then dried (MgSO4). The solvent was evaporated in vacuo to give 4.0 g of an oil, which was purified by column chromatography on silica gel (150 g) using a mixture of hep- tane and ethyl acetate (8:2) as eluent. This afforded 3.1 g (79 %) of 4-diphenylamino- butyronitrile.

The above butyronitrile (3.1 g, 13 mmol) was mixed with 96 % ethanol (40 ml) and potassium hydroxide (2.0 g). The mixture was heated at reflux temperature overnight. The solvent was evaporated in vacuo, and the residue was dissolved in water (200 ml) and washed with diethyl ether (2 x 25 ml). The solution was acidified with 1 N hydrochloric acid and the oily precipitate was extracted with ethyl acetate (2 x 100 ml), dried (MgSO4) and the solvent was evaporated in vacuo to give 1.9 g (58 %) of 4- diphenylaminobutyric acid.

4-(4-Piperidyl)imidazole dihydrochloride (1.8 g, 8.0 mmol), was stirred in dry dichloromethane (10 ml) under an atmosphere of nitrogen, Λ/,Λ/-diisopropyl-Λ/-ethyl- amine (2.8 ml, 16.0 mmol) was added and the mixture was stirred room temperature for 30 minutes. The above butyric acid (1.02 g, 4.0 mmol) was dissolved in dry di- chloromethane (6 ml) under an atmosphere of nitrogen. 1-Hydroxy-7-azabenzo- triazole (0.54 g, 4.0 mmol) and Λ/-(3-dimethylaminopropyl)-ΛT-ethylcarbodiimide hy- drochloride (0,77g, 4.0 mmol) were added. The mixture was stirred for 15 minutes and then this activated reaction mixture was added to the reaction mixture first prepared. The combined reaction mixtures were stirred overnight at room temperature, diluted with dichloromethane (25 ml) and washed with water (2 x 20 ml). The organic phase was dried (MgSO4) and the solvent was evaporated in vacuo to give an oil, which was purified by column chromatography on silicagel (100 g) using a mixture of ethyl acetate and methanol (8:2) as eluent. This afforded 0.95 g (61 %) of the title compound.

TLC: Rf = 0.52 (SiO2: ethyl acetate/methanol = 8:2).

1H NMR (DMSO-d6, 400 MHz): 1.28-1.48 (m, 2H) 1.78 (t, 2H) 1.87 (d, 2H) 2.37 (m, 2H) 2.60-2.79 (m, 2H) 3.05 (t, 1 H) 3.71 (t, 2H) 3.84 (d, 1 H) 4.40 (d, 1 H) 6.67-6.79 (bs, 1 H) 6.90 (t, 2H) 7.00 (d, 4H) 7.25 (t, 4H) 7.50 (s, 1 H) 11.6-11.9 (bs, 1 H).

EXAMPLE 5

5-(4-(4-(1H-lmidazol-4-yl)-piperidin-1-yl)butyl)-10,11-dihydro-5H-dibenzo[/-),/]azepine

Figure imgf000035_0001

Following method B 4-(4-piperidyl)imidazole dihydrochloride (0.12 g, 0.53 mmol), 5- (4-chloro-1-butyl)-10,11-dihydro-5H-dibenzo[b,/]azepine (0.15 g, 0.53 mmol), potassium carbonate (0.22 g, 1.6 mmol) and potassium iodide (0.18 g, 1.1 mmol) were mixed in acetonitrile and the mixture was heated at reflux temperature for 48 h. After cooling, water (10 ml) was added followed by ethyl acetate (10 ml) and the phases were separated. The aqueous phase was extracted with ethyl acetate (10 ml), the combined organic extracts were washed with brine (10 ml), dried (MgSO ) and evaporated in vacuo. The residue was purified by column chromatography on silica gel (10 ml) using a mixture of ethyl acetate and methanol (4:1) as eluent, affording 0.94 g (20 %) of the title compound. TLC: Rf = 0.05 (SiO2: ethyl acetate/methanol = 4:1 ).

LCMS: 401.4 (MH+).

PHARMACOLOGICAL METHODS

The ability of the compounds to interact with the histamine H3 receptor was determined by the following in vitro binding assays.

Binding assay I Rat cerebral cortex was homogenized in ice cold K-Hepes, 5 mM MgCI2 pH 7.1 buffer. After two differential centrifugations the last pellet was resuspended in fresh Hepes buffer containing 1 mg/ml bacitracin. Aliquots of the membrane suspension (400 mg/ml) were incubated for 60 min at 25 °C with 30 pM [125l]-iodoproxifan, a known histamine H3 receptor antagonist, and the test compound at various concen- trations. The incubation was stopped by dilution with ice-cold medium, followed by rapid filtration through Whatman GF/B filters pretreated for 1 h with 0.5 % polyethyle- neimine. The radioactivity retained on the filters was counted using a Cobra II auto gamma counter. The radioactivity of the filters was indirectly proportional to the binding affinity of the tested compound. The results were analyzed by nonlinear regres- sion analysis.

Binding assay II

The H3-receptor agonist ligand R-α-methyl[3H]histamine was incubated with isolated rat cortex cell-membranes at 25 °C for 1 h, followed by a filtration of the incubate through Whatman GF/B filters. Radioactivity retained on the filters was measured using a beta counter.

Male Wistar rats (150-200 g) were decapitated and cerebral cortex was quickly dissected out and frozen immediately on dry ice. Tissue was kept at -80 °C until mem- brane preparation. During the membrane preparation the tissue was kept on ice all the time. Rat cerebral cortex was homogenized in 10 volumes (w/w) ice-cold Hepes buffer (20 mM Hepes, 5 mM MgCI2 pH 7.1 (KOH) + 1 mg/ml bacitracin) using an Ul- tra-Turrax homogenizer for 30 seconds. The homogenate was centrifuged at 140 g in 10 min. The supernatant was transferred to a new test tube and centrifuged for 30 min at 23 000 g. Pellet was resuspended in 5-10 ml Hepes buffer, homogenized and centrifuged for 10 min at 23 000 g. This short centrifugation step is repeated twice. After the last centrifugation the pellet was resuspended in 2-4 ml Hepes buffer and the protein concentration was determined. The membranes were diluted to a protein concentration of 5 mg/ml using Hepes buffer, aliquoted and stored at -80 °C until use

50 μl test compound, 100 μl membrane (200 μg/ml), 300 μl. Hepes buffer and 50 μl R-α-methyl[3H]histamine (1 nM) were mixed in a test tube. The compounds to be tested were dissolved in DMSO and further diluted in H2O to the desired concentrations. Radioligand and membranes were diluted in Hepes buffer + 1 mg/ml bacitracin. The mixture was incubated for 60 min at 25 °C. Incubation was terminated by adding 5 ml ice-cold 0.9 % NaCI, followed by rapid filtration through Whatman GF/B filters pre-treated for 1 h with 0.5 % polyethyleneimine. The filters were washed with 2 x 5 ml ice-cold NaCI. To each filter a 3 ml scintillation cocktail was added and the radioactivity retained was measured with a Packard Tri-Carb beta counter.

IC50 values were calculated by non-linear regression analysis of binding curves (6 points minimum) using the windows program GraphPad Prism, GraphPad software, USA.

When tested, the present compounds of the formula I generally showed a high binding affinity to the histamine H3 receptor.

Preferably, the compounds according to the invention have an IC50 value as determined by one or both of the assays of less than 1 μM, more preferred of less than 500 nM and even more preferred of less than 100 nM.

The ability of the present compounds to reduce weight was determined using the in vivo open cage Schedule-fed rat model. The open cage Schedule-fed rat model

Sprague-Dawley (SD) male rats of an age of about VΛ. to 2 months and a weight of about 250 g were habituated to the presence of food (Altromin pelleted rat chow) in their home cage only during three hours in the morning from 9 to12 a.m. all days a week. Water was present ad libitum. When the consumption of food had stabilised after 7 to 9 days, the animals were ready for use.

The animals were tested twice a week. During the test sessions, the test compound was administered intraperitoneally 30 minutes before the start of the sessions. One group of 9 animals were administered the test compound at a dose of 15 mg/kg and another group of 11 animals were administered the test compound at a dose of 30 mg/kg. A control group of 11 animals was administered the vehicle consisting of NaCI 0.9 % and Chremophor 5 %. Food and water intake were monitored at 1 , 2 and 3 h post administration.

During the test period the animals were weighed weekly and if necessary extra food was given in order to ensure that the weight gain was 3 to 5 g per week corresponding to the normal weight gain for SD male rats at this age.

Any side effects were rapidly be discovered (barrel-rolling, bushy fur etc.) since the animals were kept in transparent plastic cages to enable continuous monitoring.

Claims

1. A compound of the general formula I
Figure imgf000039_0001
wherein
R1 is hydrogen or a functional group, which can be converted to hydrogen in vivo;
R2 is hydrogen, cyano, halogen or Cι-6-alkyl; wherein Ci-e-alkyl is optionally substituted with cyano, halogen, amino, nitro, trifluoromethyl or Cι-6-alkoxy;
X is -C(=O)-, -C(=S)- or -CH2-;
n is 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10; and
R3 and R4 independently are
C3-8-cycloalkyl optionally substituted with halogen, C-ι-6-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl;
aryl optionally substituted with halogen, Cι-6-alkoxy, C-ι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl;
heteroaryl optionally substituted with halogen, C-i-β-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3_8-cycloalkyl, aryl or heteroaryl; or d-6-alkyl optionally substituted with halogen, Cι_6-alkoxy, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl; wherein C3-8-cycloalkyl, aryl and heteroaryl optionally are substituted with halogen, C-ι-6-alkoxy, Ci-6-alkyl, trifluoromethyl, nitro, amino or cyano;
which groups R3 and R4 optionally may be connected by one or more bridging linkers to form, together with the nitrogen atom to which they are attached, a mono-, bi- or polycyclic ring system;
as well as any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R3 and R4 optionally may be connected by one or more bridging linkers independently selected from a bond, Cι--.-alkylene, C2-4-alkenylene, -(CH2)o-4-O-(CH2)o-4-> -(CH2)o-4-S-(CH2)o-4-, phenylene and biphenylene to form, together with the nitrogen atom to which they are attached, a mono-, bi- or polycyclic ring system.
3. A compound according to any one of the preceding claims wherein R1 and R2 are both hydrogen.
4. A compound according to any one of the preceding claims wherein X is -C(=0)- or -CH2-.
5. A compound according to any one of the preceding claims wherein n is 2, 3 or 4.
6. A compound according to any one of the preceding claims wherein R3 and R4 are both aryl optionally substituted with halogen, d-β-alkoxy, Cι-6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl.
7. A compound according to claim 6 wherein R3 and R4 are both phenyl optionally substituted with halogen, C-ι-6-alkoxy, C-ι_6-alkyl, trifluoromethyl, nitro, amino, cyano, C3-8-cycloalkyl, aryl or heteroaryl.
8. A compound according to claim 7 wherein R3 and R4 are both phenyl.
9. A compound according to any one of the preceding claims wherein R3 and R4 are connected by one or more bridging linkers selected from a bond, C-ι-4-alkylene, C2. -alkenylene, -(CH2)o-4-O-(CH2)o-4-, -(CH2)o-4-S-(CH2)o-4-, phenylene and bi- phenylene to form, together with the nitrogen atom to which they are attached, a mono-, bi-, tri- or tetracyclic system.
10. A compound according to claim 9 wherein R3 and R4 are connected by one bridging linker to form, together with the nitrogen atom to which they are attached, a tri- cyclic or tetracyclic system.
11. A compound according to claim 10 wherein the linker is -S-, phenylene,
Figure imgf000041_0001
such as oxyethylene or oxypropylene or Ci. -alkylene such as ethylene or propylene, preferably ethylene.
12. A compound according to claim 11 wherein the linker is ethylene.
13. A compound according to any one of the claims 1 to 12 for use as a medicament.
14. A pharmaceutical composition comprising, as an active ingredient, at least one compound according to any one of the claims 1 to 12 together with one or more pharmaceutically acceptable carriers or diluents.
15. A pharmaceutical composition according to claim 14 in unit dosage form, com- prising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg of the compound according to any one of the claims 1 to 12.
16. Use of a compound according to any one of the claims 1 to 12 for the preparation of a medicament for the treatment and/or prevention of disorders and diseases related to the histamine H3 receptor.
17. Use of a compound according to any one of the claims 1 to 12 for the preparation of a medicament for the treatment and/or prevention of disorders and diseases, in which an inhibition of the histamine H3 receptor has a beneficial effect.
18. Use of a compound according to any one of the claims 1 to 12 for the preparation of a medicament having H3 antagonistic action.
19. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the reduction of weight.
20. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of overweight or obesity.
21. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the suppression of appetite or satiety induction.
22. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the prevention and/or treatment of disorders and diseases related to overweight or obesity.
23. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the prevention and/or treatment of eating disorders such as bulimia and binge eating.
24. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of IGT.
25. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of Type 2 diabetes.
26. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from IGT to Type 2 diabetes.
27. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the delaying or prevention of the progression from non-insulin requiring Type 2 diabetes to insulin requiring Type 2 diabetes.
28. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the serotonin-3 receptor (5-HT3) such as for use in the treatment of emesis.
29. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the vanilloid receptor such as for use in the treatment of pain, neurogenic inflammation or obesity.
30. Use of a compound according to any one of the claims 1 to 12 for the preparation of a pharmaceutical composition for the treatment and/or prevention of diseases and disorders related to the alpha-2 adrenergic receptor such as for use as a sleep inducing agent.
31. A method for the treatment and/or prevention of disorders or diseases related to the H3 histamine receptor the method comprising administering to a subject in need thereof an effective amount of a compound according to any one of the claims 1 to 12 or a pharmaceutical composition comprising the same.
32. The method according to claim 31 , wherein the effective amount of the compound is in the range of from about 0.05 mg to about 2000 mg, preferably from about 0.1 mg to about 1000 mg and especially preferred from about 0.5 mg to about 500 mg per day.
PCT/DK2000/000186 1999-04-26 2000-04-14 Piperidyl-imidazole derivatives, their preparations and therapeutic uses WO2000064884A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DKPA199900565 1999-04-26
DKPA199900565 1999-04-26

Publications (1)

Publication Number Publication Date
WO2000064884A1 true true WO2000064884A1 (en) 2000-11-02

Family

ID=8094986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000186 WO2000064884A1 (en) 1999-04-26 2000-04-14 Piperidyl-imidazole derivatives, their preparations and therapeutic uses

Country Status (1)

Country Link
WO (1) WO2000064884A1 (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004637A1 (en) * 2001-07-02 2003-01-16 Banyu Pharmaceutical Co., Ltd. Utilization of histamine receptor h3 gene participating in body weight or food intake control
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
WO2003059342A1 (en) * 2002-01-11 2003-07-24 Abbott Laboratories Histamine-3 receptor ligands for diabetic conditions
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
WO2005051390A1 (en) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
WO2006019833A1 (en) * 2004-07-26 2006-02-23 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117416A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US8829041B2 (en) 2006-06-23 2014-09-09 Abbvie Inc. Cyclopropyl amine derivatives
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197840A1 (en) * 1985-03-26 1986-10-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) (Imidazolyl-4) piperidines, their preparation and their therapeutical use
WO1993020061A1 (en) * 1992-04-01 1993-10-14 The University Of Toledo 4-[4'-piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof
WO1995011894A1 (en) * 1993-10-29 1995-05-04 The University Of Toledo Histamine h3-receptor antagonists and therapeutic uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197840A1 (en) * 1985-03-26 1986-10-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) (Imidazolyl-4) piperidines, their preparation and their therapeutical use
WO1993020061A1 (en) * 1992-04-01 1993-10-14 The University Of Toledo 4-[4'-piperidinyl or 3'-pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof
WO1995011894A1 (en) * 1993-10-29 1995-05-04 The University Of Toledo Histamine h3-receptor antagonists and therapeutic uses thereof

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004637A1 (en) * 2001-07-02 2003-01-16 Banyu Pharmaceutical Co., Ltd. Utilization of histamine receptor h3 gene participating in body weight or food intake control
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
US7767881B2 (en) 2001-07-02 2010-08-03 Banyu Pharmaceutical Co., Ltd. Utilization of histamine receptor h3 gene participating in body weight or food intake control
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
EP2305648A1 (en) 2001-12-21 2011-04-06 Novo Nordisk A/S Amide derivatives useful as glucokinase activators
WO2003059342A1 (en) * 2002-01-11 2003-07-24 Abbott Laboratories Histamine-3 receptor ligands for diabetic conditions
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2005030797A2 (en) 2003-09-30 2005-04-07 Novo Nordisk A/S Melanocortin receptor agonists
WO2005051390A1 (en) * 2003-10-29 2005-06-09 Merck Sharp & Dohme Limited E-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (vr1) for the treatment of pain
EP2298337A2 (en) 2003-12-09 2011-03-23 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
EP2444397A1 (en) 2004-01-06 2012-04-25 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
JP2008507579A (en) * 2004-07-26 2008-03-13 イーライ リリー アンド カンパニー Oxazole derivatives as histamine h3 receptor agents, manufacturing and therapeutic uses
US7666871B2 (en) 2004-07-26 2010-02-23 Eli Lilly And Company Oxazole derivatives as histamine H3 receptor agents, preparation and therapeutic uses
WO2006019833A1 (en) * 2004-07-26 2006-02-23 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
CN1989115B (en) 2004-07-26 2012-03-21 伊莱利利公司 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
EP2377856A1 (en) 2005-07-14 2011-10-19 Novo Nordisk A/S Urea glucokinase activators
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US8829041B2 (en) 2006-06-23 2014-09-09 Abbvie Inc. Cyclopropyl amine derivatives
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011104379A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011117416A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012130866A1 (en) 2011-03-28 2012-10-04 Novo Nordisk A/S Novel glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use

Similar Documents

Publication Publication Date Title
US6437147B1 (en) Imidazole compounds
US5750540A (en) 1,4-di-substituted piperidine derivatives
US4929618A (en) Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same
US20030195190A1 (en) Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US5017573A (en) Indazole-3-carboxylic acid derivatives
US7776897B2 (en) Triazole derivative or salt thereof
US20030186963A1 (en) Substituted piperidines
US20030191112A1 (en) Novel substituted piperidines
WO2002040457A1 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
Boido et al. Synthesis and preliminary pharmacological evaluation of some cytisine derivatives
EP0449186A2 (en) N-aralkyl piperidine derivatives as psychotropic drugs
WO2005044192A2 (en) Triazole compounds and uses related thereto
WO2001013917A1 (en) Npy antagonists: spiroisoquinolinone derivatives
WO2004054973A2 (en) Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
US20070105834A1 (en) Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
US5034401A (en) Derivatives of (1-hydroxy-2-piperidylalkyl-indol-2-ones, 2-quinolinones, 2-benzo(B)azapinones, benzimidazol-2-ones, and quinazolin-2-ones, their preparation and their application in therapeutics
WO2000063208A1 (en) Substituted imidazoles, their preparation and use
US6569849B1 (en) N-Substituted azaheterocyclic compounds
WO1999048888A1 (en) Imidazolone anorectic agents: ii. phenyl derivatives
WO1993002052A1 (en) 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
WO2005123724A1 (en) 2,4-diaminoquinazolines for spinal muscular atrophy
WO2002032896A1 (en) Furazanyl-triazole derivates for the treatment of diseases
WO2007002361A2 (en) 3-fluoro-piperidine t-type calcium channel antagonists
WO2003031432A1 (en) Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US6727364B2 (en) Triazole compounds useful in treating diseases associated with unwanted cytokine activity

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP